Copyright © 2021. Inderes Oyj. All rights reserved.
Käyttäjätili

Hei!

Luo ilmainen tili jotta voit seurata yrityksiä, osallistua foorumin keskusteluun sekä kommentoida meidän sisältöä. Valitse sinulle sopivin tili.

Oliko sinulla jo tili?

Kirjaudu sisään

Carasent ASA

Analyytikko

Sisäpiirin kaupat

Nettovaikuttavuus

Tiedotteet
30.3.
2021

Redeye increases its estimates and fair value range for Carasent. We argue that the acquisition of Avans Soma was strategically and financially sound, and we expect an accelerated Norwegian expansion, with a Webdoc launch in the neighboring country by H2’21 or early 2022. Carasent merits a premium, as it has >90% recurring revenues in a non-cyclical and steadily growing market, coupled with net retention numbers of 115-120%.

Tiedotteet
16.10.
2020

Redeye initiates coverage of Carasent, the Norwegian holding company of the electronic medical record (EMR) developer Evimeria. This emerging compounder offers an attractive growth play on healthcare digitization with notable protection from its strong moats. Near-term catalysts include expansion to neighboring countries.

Read more and download the Research Report

Carasent ASA